Dahong Yu

936 total citations
7 papers, 695 citations indexed

About

Dahong Yu is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Dahong Yu has authored 7 papers receiving a total of 695 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Endocrinology, Diabetes and Metabolism and 2 papers in Surgery. Recurrent topics in Dahong Yu's work include Peroxisome Proliferator-Activated Receptors (3 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (2 papers) and Lipoproteins and Cardiovascular Health (2 papers). Dahong Yu is often cited by papers focused on Peroxisome Proliferator-Activated Receptors (3 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (2 papers) and Lipoproteins and Cardiovascular Health (2 papers). Dahong Yu collaborates with scholars based in United States, United Kingdom and Canada. Dahong Yu's co-authors include Steven E. Kahn, Barbara G. Kravitz, Giancarlo Viberti, Rury R. Holman, Bernard Zinman, William H. Herman, John M. Lachin, Steven M. Haffner, R. Paul Aftring and Mark Heise and has published in prestigious journals such as Journal of the American College of Cardiology, Diabetes Care and Diabetes.

In The Last Decade

Dahong Yu

7 papers receiving 665 citations

Peers

Countries citing papers authored by Dahong Yu

Since Specialization

Citations

This map shows the geographic impact of Dahong Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dahong Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dahong Yu more than expected).

Fields of papers citing papers by Dahong Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dahong Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dahong Yu. The network helps show where Dahong Yu may publish in the future.

Co-authorship network of co-authors of Dahong Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Dahong Yu. A scholar is included among the top collaborators of Dahong Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dahong Yu. Dahong Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial 2022 ·Journal of the American Academy of Dermatology ·Khaled Ezzedine, Elena Peeva, Yuji Yamaguchi, Lori Ann Cox, Anindita Banerjee, George Han, Iltefat Hamzavi, Anand K. Ganesan, Mauro Picardo, Diamant Thaçi, John E. Harris, Jung Min Bae, Katsuhiko Tsukamoto, Rodney Sinclair, Amit G. Pandya, (unknown), Dahong Yu, Kavita Gandhi, Michael S. Vincent, Brett King	79
2	Association of Sirtuin 1 Gene Polymorphisms with the Risk of Coronary Heart Disease in Chinese Han Patients with Type 2 Diabetes Mellitus 2022 ·Journal of Diabetes Research ·(unknown), (unknown), (unknown), Xiaowei Ma, Difei Lu, Dahong Yu, Na Yu, Junqing Zhang, Jianping Li, Xiaohui Guo	5
3	Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain 2009 ·Diabetes Care ·Steven E. Kahn, Steven M. Haffner, Giancarlo Viberti, William H. Herman, John M. Lachin, Barbara G. Kravitz, Dahong Yu, Gitanjali Paul, Rury R. Holman, Bernard Zinman, (unknown)	30
4	Rosiglitazone-Associated Fractures in Type 2 Diabetes 2008 ·Diabetes Care ·Steven E. Kahn, Bernard Zinman, John M. Lachin, Steven M. Haffner, William H. Herman, Rury R. Holman, Barbara G. Kravitz, Dahong Yu, Mark Heise, R. Paul Aftring, Giancarlo Viberti, (unknown)	411
5	Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy 2006 ·Diabetes and Vascular Disease Research ·Dahong Yu, Susan J. Murdoch, Shamik Parikh, Santica M. Marcovina, Alexander R. Cobitz, Hongzi Chen, John D. Brunzell	17
6	Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes 2006 ·Diabetes ·Steven E. Kahn, Bernard Zinman, Steven M. Haffner, Mark O’Neill, Barbara G. Kravitz, Dahong Yu, Martin I. Freed, William H. Herman, Rury R. Holman, Nigel C. Jones, John M. Lachin, Giancarlo Viberti, (unknown)	149
7	1124-192 Rosiglitazone reduces novel biomarkers of cardiovascular disease in subjects with type 2 diabetes mellitus already on statin therapy 2004 ·Journal of the American College of Cardiology ·John D. Brunzell, Santica Marcovina, Dahong Yu, Alexander R. Cobitz, Errol Gould, Hongzi Chen, Lisa A. Porter	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact